The emergence of drug-resistant fungi poses a major threat to human health. Despite
advances in preventive, diagnostic, and therapeutic interventions, resistant fungal infections …

Fungal infections, named mycosis, can cause severe invasive and systemic diseases that
can even lead to death. In recent years, epidemiological data have recorded an increase in …

Fungal infections impact the lives of at least 12 million people every year, killing over 1.5
million. Wide-spread use of fungicides and prophylactic antifungal therapy have driven …

Invasive mycoses have become important causes of morbidity and mortality in
immunocompromised patients. New approaches for antifungal therapy are required to meet …

For the past 50 years, fungal secondary metabolites have revolutionized medicine yielding
blockbuster drugs and drug leads of enormous therapeutic and agricultural potential. Since …

The rate of fungal infections is increasing rapidly, and pathogenesis of their species is poorly
understood. Among fungi, Candida species are a major cause of morbidity and mortality …

Despite abundant research in the field of antifungal drug discovery, fungal infections remain
a significant healthcare burden. There is an emerging need for the development of novel …

Introduction: Morbidity and mortality associated with invasive fungal infections (IFIs) remains
unacceptably high. Such diseases represent a substantial burden to the healthcare system …

Microorganisms are known as important sources of natural compounds that have been
studied and applied for different purposes in distinct areas. Specifically, in the …

Several new antifungal agents, including novel compounds in familiar classes and entirely
new classes targeting previously untapped mechanisms, are in various stages of the drug …